CUE HEALTH INC (HLTH) Fundamental Analysis & Valuation

NASDAQ:HLTH • US2297901009

0.0434 USD
-0.02 (-29.77%)
At close: Jun 5, 2024
0.0489 USD
+0.01 (+12.67%)
After Hours: 6/5/2024, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This HLTH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

HLTH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. The financial health of HLTH is average, but there are quite some concerns on its profitability. While showing a medium growth rate, HLTH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. HLTH Profitability Analysis

1.1 Basic Checks

  • In the past year HLTH has reported negative net income.
  • HLTH had a negative operating cash flow in the past year.
  • HLTH had negative earnings in 4 of the past 5 years.
  • HLTH had negative operating cash flow in 4 of the past 5 years.
HLTH Yearly Net Income VS EBIT VS OCF VS FCFHLTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 100M -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -109.92%, HLTH is doing worse than 81.68% of the companies in the same industry.
  • HLTH has a worse Return On Equity (-149.25%) than 76.44% of its industry peers.
Industry RankSector Rank
ROA -109.92%
ROE -149.25%
ROIC N/A
ROA(3y)-42.89%
ROA(5y)-43.77%
ROE(3y)-56.89%
ROE(5y)-73.2%
ROIC(3y)N/A
ROIC(5y)N/A
HLTH Yearly ROA, ROE, ROICHLTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -50 -100

1.3 Margins

  • HLTH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HLTH Yearly Profit, Operating, Gross MarginsHLTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. HLTH Health Analysis

2.1 Basic Checks

  • HLTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, HLTH has more shares outstanding
  • Compared to 1 year ago, HLTH has an improved debt to assets ratio.
HLTH Yearly Shares OutstandingHLTH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M
HLTH Yearly Total Debt VS Total AssetsHLTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

  • HLTH has an Altman-Z score of -4.83. This is a bad value and indicates that HLTH is not financially healthy and even has some risk of bankruptcy.
  • HLTH has a Altman-Z score of -4.83. This is in the lower half of the industry: HLTH underperforms 68.59% of its industry peers.
  • There is no outstanding debt for HLTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.83
ROIC/WACCN/A
WACC9.06%
HLTH Yearly LT Debt VS Equity VS FCFHLTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 2.54 indicates that HLTH has no problem at all paying its short term obligations.
  • HLTH has a Current ratio (2.54) which is in line with its industry peers.
  • HLTH has a Quick Ratio of 2.22. This indicates that HLTH is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.22, HLTH is in line with its industry, outperforming 47.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 2.22
HLTH Yearly Current Assets VS Current LiabilitesHLTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. HLTH Growth Analysis

3.1 Past

  • HLTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -153.47%.
  • The Revenue for HLTH has decreased by -85.32% in the past year. This is quite bad
  • Measured over the past years, HLTH shows a very strong growth in Revenue. The Revenue has been growing by 45.56% on average per year.
EPS 1Y (TTM)-153.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-357.14%
Revenue 1Y (TTM)-85.32%
Revenue growth 3Y45.56%
Revenue growth 5YN/A
Sales Q2Q%-87.19%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.29% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 52.69% on average over the next years. This is a very strong growth
EPS Next Y56.3%
EPS Next 2Y31.95%
EPS Next 3Y24.25%
EPS Next 5Y17.29%
Revenue Next Year-18.38%
Revenue Next 2Y25.41%
Revenue Next 3Y43.74%
Revenue Next 5Y52.69%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
HLTH Yearly Revenue VS EstimatesHLTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
HLTH Yearly EPS VS EstimatesHLTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. HLTH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HLTH. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HLTH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HLTH Price Earnings VS Forward Price EarningsHLTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HLTH Per share dataHLTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as HLTH's earnings are expected to grow with 24.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.95%
EPS Next 3Y24.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HLTH Dividend Analysis

5.1 Amount

  • HLTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

HLTH Fundamentals: All Metrics, Ratios and Statistics

CUE HEALTH INC

NASDAQ:HLTH (6/5/2024, 8:00:01 PM)

After market: 0.0489 +0.01 (+12.67%)

0.0434

-0.02 (-29.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13
Earnings (Next)08-07
Inst Owners1.03%
Inst Owner Change0%
Ins Owners29.79%
Ins Owner Change0%
Market Cap6.90M
Revenue(TTM)70.97M
Net Income(TTM)-373.50M
Analysts43.33
Price Target0.51 (1075.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-56.92%
Min EPS beat(2)-120.16%
Max EPS beat(2)6.32%
EPS beat(4)1
Avg EPS beat(4)-29.65%
Min EPS beat(4)-120.16%
Max EPS beat(4)6.32%
EPS beat(8)5
Avg EPS beat(8)14.83%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.53%
Min Revenue beat(2)2.82%
Max Revenue beat(2)4.24%
Revenue beat(4)3
Avg Revenue beat(4)-3.72%
Min Revenue beat(4)-27.41%
Max Revenue beat(4)5.48%
Revenue beat(8)7
Avg Revenue beat(8)33.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.33%
PT rev (3m)-52.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-46.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-65.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-38.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.1
P/FCF N/A
P/OCF N/A
P/B 0.03
P/tB 0.03
EV/EBITDA N/A
EPS(TTM)-2.56
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0.45
BVpS1.57
TBVpS1.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -109.92%
ROE -149.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.89%
ROA(5y)-43.77%
ROE(3y)-56.89%
ROE(5y)-73.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.18%
Cap/Sales 27.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 2.22
Altman-Z -4.83
F-Score3
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)177.13%
Cap/Depr(5y)371.33%
Cap/Sales(3y)19.89%
Cap/Sales(5y)88.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-153.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-357.14%
EPS Next Y56.3%
EPS Next 2Y31.95%
EPS Next 3Y24.25%
EPS Next 5Y17.29%
Revenue 1Y (TTM)-85.32%
Revenue growth 3Y45.56%
Revenue growth 5YN/A
Sales Q2Q%-87.19%
Revenue Next Year-18.38%
Revenue Next 2Y25.41%
Revenue Next 3Y43.74%
Revenue Next 5Y52.69%
EBIT growth 1Y-45.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.74%
EBIT Next 3Y13.08%
EBIT Next 5Y20.63%
FCF growth 1Y9.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.13%
OCF growth 3YN/A
OCF growth 5YN/A

CUE HEALTH INC / HLTH FAQ

What is the ChartMill fundamental rating of CUE HEALTH INC (HLTH) stock?

ChartMill assigns a fundamental rating of 3 / 10 to HLTH.


Can you provide the valuation status for CUE HEALTH INC?

ChartMill assigns a valuation rating of 1 / 10 to CUE HEALTH INC (HLTH). This can be considered as Overvalued.


How profitable is CUE HEALTH INC (HLTH) stock?

CUE HEALTH INC (HLTH) has a profitability rating of 0 / 10.


What is the financial health of CUE HEALTH INC (HLTH) stock?

The financial health rating of CUE HEALTH INC (HLTH) is 6 / 10.